Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

Basit Öğe Kaydı
dc.contributor.authorTonyali, Onder
dc.contributor.authorCoskun, Ugur
dc.contributor.authorSener, Nur
dc.contributor.authorInanc, Mevlude
dc.contributor.authorAkman, Tulay
dc.contributor.authorUlas, Arife
dc.contributor.authorYazilitas, Dogan
dc.date.accessioned2024-04-24T17:14:28Z
dc.date.available2024-04-24T17:14:28Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC). Patients and Methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis. Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS. Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.en_US
dc.identifier.doi10.1159/000355156
dc.identifier.endpage558en_US
dc.identifier.issn0378-584X
dc.identifier.issn1423-0240
dc.identifier.issue10en_US
dc.identifier.pmid24107908
dc.identifier.scopus2-s2.0-84885585847
dc.identifier.scopusqualityQ4
dc.identifier.startpage554en_US
dc.identifier.urihttps://doi.org/10.1159/000355156
dc.identifier.urihttps://hdl.handle.net/11468/17980
dc.identifier.volume36en_US
dc.identifier.wosWOS:000325713400003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOnkologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectEarly Diseaseen_US
dc.subjectTrastuzumaben_US
dc.subjectAdjuvant Treatmenten_US
dc.subjectHer2en_US
dc.subjectPrognosisen_US
dc.titlePrognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumaben_US
dc.titlePrognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu